It's somewhat instructive that the current promise of the GLP-1s was an accidental discovery with respect to its application to broad-base addiction. My initial instinct was to suggest that intentionally developing an anti-addiction drug that is expected to have specificity may not be possible without first understanding the physiological mechanisms by which addictive substances effect dependence.
But perhaps with the emergence of GLP-1s, researchers could leverage on modelling its pharmacokinetic and pharmacodynamic properties to figure out some broadly applicable fundamental principles in their efforts to develop other drugs.
Not sure though if this makes any sense to those who are more knowledgeable in the field.
It's somewhat instructive that the current promise of the GLP-1s was an accidental discovery with respect to its application to broad-base addiction. My initial instinct was to suggest that intentionally developing an anti-addiction drug that is expected to have specificity may not be possible without first understanding the physiological mechanisms by which addictive substances effect dependence.
But perhaps with the emergence of GLP-1s, researchers could leverage on modelling its pharmacokinetic and pharmacodynamic properties to figure out some broadly applicable fundamental principles in their efforts to develop other drugs.
Not sure though if this makes any sense to those who are more knowledgeable in the field.
I think you are right and I think that evolution of perspective is underway in a lot of research programs.